New drug cocktail aims to shrink lymphoma tumors without chemo
NCT ID NCT04450173
First seen Apr 21, 2026 · Last updated Jun 17, 2026 · Updated 10 times
Summary
This study tests whether a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) can shrink tumors in people with untreated follicular lymphoma. The trial includes 40 adults with stage II to IV disease. The goal is to see if the combination works better than any single drug alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRADE 3A FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Diego
San Diego, California, 92037, United States
-
University of California, San Francisco (UCSF) Fresno
Fresno, California, 93701, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.